When Paul Conyngham drove ten hours from Sydney to Gatton, Queensland, in December 2025, he was carrying something no veterinary pharmacologist had approved: a personalized cancer vaccine designed with AI tools including ChatGPT, Gemini, Grok, and AlphaFold. His passenger was Rosie, an eight-year-old Staffordshire bull terrier mix with terminal mast cell cancer. By January 2026, after a booster injection, Conyngham was posting videos of the tumor on Rosie's leg shrinking by 75 percent. Sam Altman called it an amazing story on X. The internet agreed.
There is just one problem: nobody knows if the vaccine did anything.
"We don't know for sure what actually led to the reduction in size of Rosie's biggest tumour," Conyngham told Channel News Asia. UNSW and Conyngham have not published scientific details outside a press release and interviews, Phys.org reported. The scientific community agrees: Nick Semenkovich, a researcher at the Medical College of Wisconsin who studies AI in biomedicine but was not involved in Rosie's case, told AFP there is no way to know whether the vaccine worked as designed or how much the AI tools actually contributed.
The story has the shape of a breakthrough. A grieving owner, consumer-grade AI tools, a beloved dog beating cancer against the odds. It checks every box for virality. But the scientific evidence underlying it remains, for now, anecdote dressed in sequencing data.
Conyngham paid roughly $3,000 for genomic sequencing of Rosie and her tumor at the University of New South Wales, Fortune reported. He used large language models to study cancer therapies and AlphaFold, DeepMind's protein-structure modeling tool, to predict which mutations in Rosie's tumor might be most immunogenic. That information guided the design of a personalized mRNA vaccine delivered by a Queensland veterinarian. This appears to be the first time a personalized cancer vaccine has been designed for a dog, Fortune reported.
The approach is not inherently implausible. Personalized mRNA cancer vaccines are a genuine frontier in human oncology. BioNTech's personalized mRNA vaccine for triple-negative breast cancer, reported in Nature in early 2026, kept 10 of 14 patients disease-free. Moderna and Merck have a Phase 3 personalized cancer vaccine trial running. The biology is real.
What is missing is the publication. In science, an unpublished claim is an incomplete claim. Without the antigen selection method, dosing, or immunogenicity data available for review, the oncology community cannot assess whether the tumor shrinkage reflects immune response, random variation in a terminal dog's disease course, concurrent treatments, or the vaccine itself. Mast cell tumors in dogs vary widely in their behavior. Rosie's case has not resolved that confound.
The democratization argument has merit. Cancer treatment is expensive, slow, and heavily siloed in specialty centers. If AI tools can compress the design phase of a personalized vaccine to the point where a determined owner with a sequencing budget and a cooperative veterinarian can attempt something that previously required a pharma company's infrastructure, that matters. The $3,000 price tag for sequencing is a fraction of what a human personalized cancer vaccine currently costs.
But access without evidence is just a different kind of exclusion. If the field of AI-designed cancer vaccines is built partly on viral anecdotes that cannot be verified, the patients and pet owners who hear those stories and seek them out will be acting on hope, not signal. The risk is not that personalized cancer vaccines are fake. The risk is that Rosie's specific story is being treated as proof of concept when it is, at best, an n of one with no control group, no published methods, and no follow-up data beyond what Conyngham has shared on social media.
Rosie has since had another operation. It is unclear how long she has left to live.
What to watch next is not whether this story goes viral again. It is whether UNSW publishes any data, and whether any veterinary oncologist attempts a follow-up with a control group. Conyngham has said he is willing to share his approach. If he does, in a form scientists can actually evaluate, the Rosie story becomes something more than a heartwarming post. If he does not, the field of AI-designed cancer vaccines will have to carry on without it.
For now, the honest version of what happened is: one dog, one cancer, one very dedicated owner, and a result that is impossible to interpret without more information. That is not nothing. But it is not a breakthrough either.
† Add source linking to Fortune for this claim, OR add footnote: "Source-reported; not independently verified."